Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics announced the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel, significantly enhancing single-cell and spatial biology research. The new panel boasts a tenfold increase in plex capacity, improved per-gene sensitivity, specificity, and spatial fidelity. Key features include rapid turnaround time, customizable options, and the capability to analyze extensive tissue areas efficiently. Optimized for human and mouse species, the panel is now available for preorder, with shipments expected next month. This innovation aims to advance the exploration of molecular pathways, biomarkers, and cell interactions in various diseases.
10x Genomics, a leader in single cell and spatial biology, will be presenting at the BofA Securities 2024 Healthcare Conference. The company's management team will participate in a fireside chat on May 14 at 4:20 p.m. Pacific Time. Interested parties can access a live webcast of the event on the company's website.
Curio Bioscience reported a favorable decision from the European Unified Patent Court (UPC) regarding a patent infringement claim by 10x Genomics. The court found that Curio Seeker does not infringe on the main claim asserted by 10x Genomics and ordered Curio Bioscience not to offer any violating products in certain countries. Curio Bioscience expects no impact on its commercial business due to this ruling.
10x Genomics, Inc. reported $141.0 million in revenue for the first quarter of 2024, a 5% increase from the same period in 2023. The company introduced four major new products, including Visium HD Spatial Gene Expression and two new Chromium products powered by GEM-X. Despite revenue growth, gross margin decreased to 66% due to product mix changes. Operating expenses rose by 3% to $154.4 million, driven by higher legal expenses and facility costs. The company saw an operating loss of $61.5 million and a net loss of $59.9 million for the quarter. 10x Genomics is maintaining its full-year 2024 revenue guidance of $670 million to $690 million, anticipating 8% to 12% growth over 2023.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
